Literature DB >> 22977022

Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence.

Ritu Shah1, Surjith Vattoth, Rojymon Jacob, Fathima Fijula Palot Manzil, Janis P O'Malley, Peyman Borghei, Bhavik N Patel, Joel K Curé.   

Abstract

Radiation necrosis in the brain commonly occurs in three distinct clinical scenarios, namely, radiation therapy for head and neck malignancy or intracranial extraaxial tumor, stereotactic radiation therapy (including radiosurgery) for brain metastasis, and radiation therapy for primary brain tumors. Knowledge of the radiation treatment plan, amount of brain tissue included in the radiation port, type of radiation, location of the primary malignancy, and amount of time elapsed since radiation therapy is extremely important in determining whether the imaging abnormality represents radiation necrosis or recurrent tumor. Conventional magnetic resonance (MR) imaging findings of these two entities overlap considerably, and even at histopathologic analysis, tumor mixed with radiation necrosis is a common finding. Advanced imaging modalities such as diffusion tensor imaging and perfusion MR imaging (with calculation of certain specific parameters such as apparent diffusion coefficient ratios, relative peak height, and percentage of signal recovery), MR spectroscopy, and positron emission tomography can be useful in differentiating between recurrent tumor and radiation necrosis. In everyday practice, the visual assessment of diffusion-weighted and perfusion images may also be helpful by favoring one diagnosis over the other, with restricted diffusion and an elevated relative cerebral blood volume being seen much more frequently in recurrent tumor than in radiation necrosis.

Entities:  

Mesh:

Year:  2012        PMID: 22977022     DOI: 10.1148/rg.325125002

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  69 in total

1.  Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery.

Authors:  G Lai; A Mahadevan; D Hackney; P C Warnke; F Nigim; E Kasper; E T Wong; B S Carter; C C Chen
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

Review 2.  Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

Authors:  Alessandra Fabi; Antonello Vidiri
Journal:  Transl Lung Cancer Res       Date:  2016-12

3.  Brain Damage and Patterns of Neurovascular Disorder after Ionizing Irradiation. Complications in Radiotherapy and Radiation Combined Injury.

Authors:  Nikolai V Gorbunov; Juliann G Kiang
Journal:  Radiat Res       Date:  2021-07-01       Impact factor: 2.841

4.  Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Daniela B Almeida-Freitas; Marco C Pinho; Maria C G Otaduy; Henrique F Braga; Daniel Meira-Freitas; Claudia da Costa Leite
Journal:  Neuroradiology       Date:  2014-03-21       Impact factor: 2.804

5.  Cerebral cyst formation following stereotactic ablative irradiation for non-nasopharyngeal head and neck malignancies: imaging findings and relevant dosimetric parameters.

Authors:  K Ohtakara; H Hoshi
Journal:  Br J Radiol       Date:  2014-02-26       Impact factor: 3.039

6.  Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.

Authors:  Fabio Y Moraes; Jeff Winter; Eshetu G Atenafu; Archya Dasgupta; Hamid Raziee; Catherine Coolens; Barbara-Ann Millar; Normand Laperriere; Maitry Patel; Mark Bernstein; Paul Kongkham; Gelareh Zadeh; Tatiana Conrad; Caroline Chung; Alejandro Berlin; David B Shultz
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

7.  Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Authors:  Raymond Y Huang; Wenya Linda Bi; Michael Weller; Thomas Kaley; Jaishri Blakeley; Ian Dunn; Evanthia Galanis; Matthias Preusser; Michael McDermott; Leland Rogers; Jeffrey Raizer; David Schiff; Riccardo Soffietti; Jörg-Christian Tonn; Michael Vogelbaum; Damien Weber; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

8.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

9.  Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.

Authors:  Shiro Ohue; Shohei Kohno; Akihiro Inoue; Daisuke Yamashita; Satoshi Suehiro; Toshimoto Seno; Yoshiaki Kumon; Keiichi Kikuchi; Takanori Ohnishi
Journal:  J Neurooncol       Date:  2015-09-18       Impact factor: 4.130

Review 10.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.